Global Retirement Partners LLC Acquires Shares of 73,217 AbbVie Inc. $ABBV

Global Retirement Partners LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 73,217 shares of the company’s stock, valued at approximately $18,424,000.

Several other large investors have also recently modified their holdings of ABBV. State Street Corp lifted its position in AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC increased its position in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares during the last quarter. Bank of America Corp DE raised its stake in shares of AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after acquiring an additional 356,394 shares during the period. Norges Bank bought a new stake in shares of AbbVie in the 4th quarter worth about $5,865,055,000. Finally, Capital Research Global Investors lifted its holdings in shares of AbbVie by 0.7% in the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after acquiring an additional 177,370 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.0%

Shares of AbbVie stock opened at $263.08 on Thursday. The stock’s fifty day moving average price is $251.04 and its 200-day moving average price is $228.43. The firm has a market cap of $464.81 billion, a P/E ratio of 74.32, a P/E/G ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the firm earned $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ABBV shares. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. Citigroup boosted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Barclays upped their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $275.95.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Billionaire investor Ken Griffin increased his AbbVie position by 547% in the second quarter, highlighting institutional confidence in the company’s high dividend yield and relatively defensive business profile. Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2
• Positive Sentiment: AbbVie’s immunology franchise remains a key growth anchor, while newer medicines and its oncology pipeline are helping diversify the company beyond Humira and support its longer-term outlook. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Recent quarterly results exceeded analyst expectations, with revenue up 10.2% year over year and earnings modestly ahead of consensus. Management’s third-quarter earnings outlook also points to continued operating momentum.
• Neutral Sentiment: Analysts see AbbVie and Eli Lilly as offering different combinations of growth, pipeline potential and risk; the comparison reinforces that AbbVie is viewed more as a dividend and established-product investment than a high-growth pharmaceutical story. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Valuation is the main near-term concern. After its strong run, AbbVie trades at an elevated earnings multiple, leaving less room for disappointment if growth slows or pipeline investments take longer to pay off. Has AbbVie Stock Become Too Expensive to Buy?
• Negative Sentiment: Second-quarter oncology sales declined 2.4%, primarily because of falling Imbruvica revenue. Growth from Venclexta and newer products only partially offset that pressure, raising concerns about the pace of AbbVie’s portfolio transition. How Did ABBV’s Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.